Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Stribild

ApprovedSmall molecule

Stribild is one of 85 small molecule programs targeting Cognition. It is currently in Approved.

2

Indications

14

Total Trials

0

Active Trials

84

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

ImmunodeficiencyActive, not recruiting

CognitionApproved

Active, not recruiting

ImmunodeficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

296 competitors in Immunodeficiency

#DrugCompanyPhaseTrials

Vemlidy

Livalo

V114

Immunoglobulin G

Stribild

PPSV23

Nrtis

Darunavir/ritonavir

V116

Pegifn/rbv

Boehringer Ingelheim

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency3 trials

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01106586·708 enrolled

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01095796·707 enrolled

Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 2·NCT00869557·71 enrolled

Tenofovir2 trials

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed· Gilead logo

Gilead·Phase 3·NCT01475838·438 enrolled

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed· Gilead logo

Gilead·Phase 3·NCT01495702·439 enrolled

CLE1 trial

STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)

Unknown status·VVancouver Infectious Diseases Centre··NCT02306577·30 enrolled

Cognition1 trial

Sleep and Cognition After Atripla to Stribild Switch

Unknown status·UUniversity of Hawaii·Phase 4·NCT02283060·30 enrolled

ILD1 trial

Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet

Completed·RRadboud University Medical Center·Phase 1·NCT02325934·24 enrolled

6 more indications

Sleep Disturbance1 trial

Atripla to Stribild Switch Study to Evaluate Sleep Disturbances

Completed·—·Phase 4·NCT02477527·21 enrolled

Interaction1 trial

Interaction With HIV Antiretroviral Agents

Completed· Bayer logo

Bayer·Phase 1·NCT02556268·40 enrolled

Pilot Study1 trial

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed· Gilead logo

Gilead·Phase 3·NCT01533259·48 enrolled

HIV-Infected Individuals1 trial

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Completed·UUniversity of California, San Diego·N/A·NCT02251236·14 enrolled

Central Nervous System1 trial

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

Completed·MMassachusetts General Hospital·N/A·NCT01929759·10 enrolled

Unspecified1 trial

Renal Integrase Study

Completed·SSt Stephens Aids Trust·Phase 4·NCT02351908·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Stribild. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stribild compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stribild. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Gilead

Related News